Clinical Trials Logo

Nasopharyngeal Carcinoma clinical trials

View clinical trials related to Nasopharyngeal Carcinoma.

Filter by:

NCT ID: NCT03925896 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients

Start date: August 7, 2019
Phase: Phase 1
Study type: Interventional

In this study, a single-arm, open-labeled clinical trial will be performed to determine the safety and efficacy of EBV TCR-T cells in the treatment of recurrent/metastatic nasopharyngeal carcinoma with positive EBV infection in the Chinese population.

NCT ID: NCT03923842 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours

Dern
Start date: June 30, 2019
Phase: Phase 2
Study type: Interventional

The aim of the present investigation is to test of the modulation obtained with denosumab as "priming" therapy before the start of chemotherapy and as concurrent therapy in a population of first line NPC recurrent/metastatic patients

NCT ID: NCT03919552 Recruiting - NPC Clinical Trials

Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

Start date: January 31, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare cisplatin-based with carboplatin-based chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (NPC), in order to confirm the value of carboplatin-based chemoradiotherapy in NPC patients.

NCT ID: NCT03915132 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma

Start date: May 1, 2019
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and toxicity of Nimotuzumab combined with VMAT in the treatment of elderly patients with nasopharyngeal carcinoma (> 70 years old), and to provide high-level clinical evidence for the optimal treatment of elderly patients with nasopharyngeal carcinoma.

NCT ID: NCT03908372 Recruiting - Clinical trials for Concurrent Chemoradiotherapy

Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma

Start date: June 15, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to optimize treatment strategies for patients with stage II and III nasopharyngeal carcinoma, reduce the side effects related to treatment and improve the quality of life.

NCT ID: NCT03907826 Recruiting - Clinical trials for Recurrent Nasopharyngeal Carcinoma

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

Start date: March 1, 2020
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized controlled, phase III clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of PD-1 antibody with chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma patients.

NCT ID: NCT03904225 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis

Start date: December 14, 2018
Phase: Phase 2
Study type: Interventional

oral administration of Tegio capsules for 12 months for NPC patients with high risk of metastasis (AJCC stage T3-4N2M0 or T1-4N3M0) was tested trying to reduce distant metastasis,safety was also evaluated.

NCT ID: NCT03837808 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma

Start date: April 11, 2019
Phase: Phase 3
Study type: Interventional

This is a Phase III trial to study the effectiveness of nimotuzumab versus cisplatin combined with intensity-modulated radiation therapy (IMRT) in treating patients with stage II-III nasopharyngeal carcinoma.

NCT ID: NCT03830996 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Weekly Plasma EBV DNA for Non-metastatic Nasopharyngeal Carcinoma

Start date: February 2016
Phase:
Study type: Observational

Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southern China, Hong Kong, Taiwan, Singapore and Malaysia. It is highly associated with Epstein-Barr virus (EBV). Radiation therapy alone is indicated for early stage I to II diseases while concurrent chemoradiation is required for more advanced stage III to IVB diseases. Intensity-modulated radiation therapy (IMRT) is the standard radiation technique for NPC, in virtue of its superior target coverage and dose sparing to adjacent critical organs-at-risks. Plasma EBV DNA and other novel plasma biomarkers have been extensively investigated in NPC. Previous studies have proven their predictive and prognostic values in NPC diagnosis, surveillance and survival outcomes. Investigators would like to investigate the roles of plasma biomarkers including plasma EBV DNA on treatment response evaluation, survival and prognosis on NPC, in the modern era of precision radiation therapy. This will help provide important information on refining on the current edition of AJCC/UICC staging classification.

NCT ID: NCT03809624 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

PDL1x41BB
Start date: January 30, 2019
Phase: Phase 2
Study type: Interventional

This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination with Pembrolizumab. INBRX-105, a next generation bispecific antibody, targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor. INBRX-105 provides localized conditional T-cell co-stimulation through 4-1BB agonism.